Section A: Metabolic Surgery Research

Demand Shock Exposes Surgical Training Problem: What Bariatric Volume Collapse Reveals About the Future of Minimally Invasive Surgery Fellowship Training

Viewpoint arguing that GLP-1-driven volume contraction exposes a training mismatch in MIS and bariatric surgery. It proposes earlier MIS/robotic credentialing in residency, volume standards for centers, and fellowship recalibration.

Mortality associated biological age improves independently of weight loss after bariatric surgery

Prospective 505-patient cohort using blood-marker models of mortality-associated biological age. The authors report improved age acceleration after surgery, suggesting measurable health gain beyond pounds lost.

GLP-1 Receptor Agonists vs Bariatric Surgery in Breast Cancer

TriNetX real-world analysis of postmenopausal women with obesity and stage 0-III breast cancer comparing GLP-1 receptor agonist therapy, bariatric surgery, and combination treatment. After matching, GLP-1RA therapy was associated with lower locoregional recurrence and lower instantaneous mortality risk than bariatric surgery alone; combined surgery plus GLP-1RA had the most favorable overall survival and recurrence profile. The result is hypothesis-generating and clinically relevant because it links obesity treatment choice to cancer outcomes, while needing prospective validation.

2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome

Joint 2026 AHA/ACC/ADA/ASN CKM guideline update that explicitly places metabolic and bariatric surgery in the Stage 1-3 CKM treatment pathway, not as a last-resort intervention. The guideline gives Class IIa support for MBS in patients with obesity and inadequate response to lifestyle and/or pharmacotherapy, lowers the BMI threshold for patients with T2DM, notes longer-term advantages of RYGB over sleeve for CKM risk-factor remission, and cites large reductions in cardiovascular events and all-cause mortality in matched observational data. It also frames GLP-1-based therapy as complementary, including for post-MBS weight regain, making this a key referral and counseling document for surgeons working with cardiology, nephrology, endocrinology, and primary care.

Section B: Obesity Medicine Research

Virtual shared medical appointments for obesity and GLP-1 medications: A scalable method for optimizing care delivery

Single-site retrospective report on group virtual visits for GLP-1 medication support and lifestyle counseling. Relevant for practices trying to scale longitudinal obesity care without losing behavioral structure.

Enhancing economic modelling in obesity: integrating novel type 2 diabetes progression and obstructive sleep apnea remission - a UK case study

Updated obesity cost-effectiveness model incorporating SURMOUNT evidence, type 2 diabetes progression, OSA remission, and treatment discontinuation. Useful for payer conversations as models catch up to incretin-era outcomes.

Effects of Tirzepatide on Metabolic Parameters in Patients with Psoriasis and Obesity: 24-Week Real-World Study

Prospective 64-patient real-world study of tirzepatide in adults with psoriasis and obesity on stable ixekizumab. Adds a specialty-population angle to incretin use and cardiometabolic risk reduction.

Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes

Commentary reviewing emerging alopecia signals with GLP-1 and dual incretin therapies, likely mechanisms, and management considerations. Practical counseling item as obesity pharmacotherapy expands.

Section C: Metabolic Treatment in the News

Ozempic changed obesity treatment, but experts say the real revolution is next

ScienceDaily summarizes an AGA Gastroenterology commentary, Revisiting POWER in the GLP-1 Age, arguing that the next stage of obesity care will not be medication alone. The updated framework emphasizes personalized, multidisciplinary care that combines anti-obesity medications, endoscopic bariatric and metabolic therapies, surgery, precision medicine, and long-term clinical management.

Weight loss without muscle loss? Next-gen drugs are testing the idea

Business Insider reports on the race to develop obesity drugs that preferentially reduce fat while preserving lean mass. The piece highlights industry interest in agents such as bimagrumab and other combination strategies, with companies trying to improve the quality of weight loss rather than simply the total number of pounds lost.

FDA's concerns with unapproved GLP-1 drugs used for weight loss

FDA warns that unapproved GLP-1 products used for weight loss may include compounded, counterfeit, illegally marketed, or falsely labeled versions of semaglutide, tirzepatide, retatrutide, cagrilintide, and related ingredients. The agency stresses that unapproved versions have not undergone FDA review for safety, effectiveness, or quality and flags concerns around dosing, shipping, online sales, and research-use-only products.

Section D: Metabolic Market Movers

Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea

Lilly reported Phase 3 retatrutide data from TRIUMPH-1 and TRANSCEND-T2D-1, including up to 28.3% mean weight loss at 80 weeks and improvements in OA pain, OSA severity, and A1C. Market angle: next-gen obesity drug benchmark moves higher.

Drugmakers race to find a place in the next wave of obesity drugs

CNBC synthesis from ADA 2026 on oral GLP-1s, amylin drugs, less-frequent injections, and competition from Lilly, Novo, Pfizer, Amgen, Zealand, Structure, Roche, and AstraZeneca. Good market-wide scene-setter.

Amgen presents new data across its cardiometabolic portfolio at ADA 2026

Amgen highlighted VESALIUS-CV Repatha data in high-risk diabetes plus real-world evidence showing low persistence with GLP-1 therapy. Market angle: chronic-treatment durability and cardiometabolic adjacency are becoming differentiators.

Real-world evidence: shaping obesity treatment beyond clinical trials

Company Q&A on real-world evidence in obesity, including claims that 50-60% of patients may not remain on therapy long term and that discontinuation can drive weight regain. Good business/clinical bridge for why monthly or less frequent agents could matter.